Comprehensive Molecular Study of Endocrine Tumors in Participants Aged 4 and Older Collecting Tissue Samples During Surgery or Biopsy to Improve Diagnosis and Treatment

What this Trial Is About

Endocrine neoplasms, including tumors of the thyroid, parathyroid, adrenal gland, pancreas, and neuroendocrine tissues, are rapidly increasing in incidence in the United States. These tumors can be challenging to distinguish between benign and malignant forms. Researchers aim to study the molecular changes involved in the development and progression of these cancers to improve diagnosis and treatment options. The study collects tissue samples from participants scheduled for surgery or biopsy of endocrine tumors. Before surgery, blood and urine samples are taken. During the operation, pieces of tumor or precancerous growths, along with nearby normal tissue, are collected for research. No investigational therapy is administered. After surgery, participants receive routine care and have a follow-up clinic visit about 6 weeks later, with potential yearly follow-ups by phone or in person. Participants provide important biological samples to help researchers create genetic, epigenetic, metabolomic, and proteomic profiles of endocrine neoplasms. The study measures how these profiles can distinguish between benign and malignant tumors over a period of up to 10 years. Researchers also analyze gene expression and other molecular features from the tissue collected. Participants will be monitored during their surgery recovery and followed long term to correlate tissue findings with clinical outcomes.

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms